Julian Adams
Vorsitzender bei ELICIO THERAPEUTICS, INC.
Vermögen: 24 806 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Robert Connelly | M | 63 |
Elicio Therapeutics, Inc. (Old)
 Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 6 Jahre |
| Robert Ruffolo | M | 74 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 6 Jahre |
| Thomas Bures | M | 49 | 7 Jahre | |
| Carol Ashe | F | 66 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 4 Jahre |
| James Geraghty | M | 69 | 7 Jahre | |
| Megan Filoon | F | - | 1 Jahre | |
| Seth Tasker | M | 45 | 16 Jahre | |
| Anthony Evnin | M | 83 |
Infinity Discovery, Inc.
| 23 Jahre |
| Norman Selby | M | 71 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 21 Jahre |
| Christopher Kiritsy | M | 59 | 8 Jahre | |
| Yekaterina Chudnovsky | F | 39 | 2 Jahre | |
| Michael Burns | M | - |
Princess Margaret Cancer Foundation
| 6 Jahre |
| Ann J. Barbier | M | 59 | 6 Jahre | |
| Allen Nissenson | M | 77 | 4 Jahre | |
| Annette Matthies | M | 47 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 3 Jahre |
| Christopher Haqq | M | 58 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 5 Jahre |
| Peter DeMuth | M | 38 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 7 Jahre |
| Esther Welkowsky | F | - |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 4 Jahre |
| Mary Coelho | F | 62 | 1 Jahre | |
| Karen Wilson | F | 61 | 1 Jahre | |
| Janice Fukakusa | F | 69 |
Princess Margaret Cancer Foundation
| - |
| Jack Fleischmann | M | - |
Princess Margaret Cancer Foundation
| - |
| Angelika Amon | F | - |
Stand Up To Cancer
 Stand Up To Cancer Miscellaneous Commercial ServicesCommercial Services Stand Up To Cancer (SU2C) is a non-profit organization that raises funds to accelerate cancer research and bring new therapies to patients quickly. SU2C is based in Los Angeles, CA. Established in 2008 by media and entertainment leaders, SU2C engages the public in supporting a collaborative model of cancer research, increasing awareness about cancer prevention, and highlighting progress in the fight against the disease. The organization has over 3,000 scientists from more than 210 institutions involved in SU2C-funded research projects. The American Association for Cancer Research (AACR) and a scientific advisory committee oversee grants administration and provide expert review of research progress. | - |
| John Glaspy | M | - |
Stand Up To Cancer
Stand Up To Cancer Miscellaneous Commercial ServicesCommercial Services Stand Up To Cancer (SU2C) is a non-profit organization that raises funds to accelerate cancer research and bring new therapies to patients quickly. SU2C is based in Los Angeles, CA. Established in 2008 by media and entertainment leaders, SU2C engages the public in supporting a collaborative model of cancer research, increasing awareness about cancer prevention, and highlighting progress in the fight against the disease. The organization has over 3,000 scientists from more than 210 institutions involved in SU2C-funded research projects. The American Association for Cancer Research (AACR) and a scientific advisory committee oversee grants administration and provide expert review of research progress. | - |
| Andrew Irvine | M | 72 |
Princess Margaret Cancer Foundation
| 8 Jahre |
| Fiorella Kostoris | F | 79 |
Massachusetts Institute of Technology
| 44 Jahre |
| Brian Piekos | M | 49 | 1 Jahre | |
| Andrew Hoffman | M | 62 |
Princess Margaret Cancer Foundation
| 8 Jahre |
| Donald R. Sadoway | M | - |
Massachusetts Institute of Technology
| 46 Jahre |
| M. Marianne Harris | F | 66 |
Princess Margaret Cancer Foundation
| - |
| Annie Ropar | F | - |
Princess Margaret Cancer Foundation
| 7 Jahre |
| Mary-Alice Vuicic | F | 56 |
Princess Margaret Cancer Foundation
| 10 Jahre |
| John D. Joannopoulos | M | - |
Massachusetts Institute of Technology
| 46 Jahre |
| Stuart Waugh | M | - |
Princess Margaret Cancer Foundation
| 10 Jahre |
| Jochen Tilk | M | 60 |
Princess Margaret Cancer Foundation
| - |
| Richard Elgin Rooney | M | - |
Princess Margaret Cancer Foundation
| 7 Jahre |
| Joy Seymour | F | - | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Lawrence Bloch | M | 58 | 11 Jahre | |
| Richard Kogan | M | 81 | 21 Jahre | |
| Jaren Madden | F | - | 7 Jahre | |
| Gerald Quirk | M | 56 | 6 Jahre | |
| Ofer Gonen | M | 50 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 7 Jahre |
| Darlene Deptula-Hicks | F | 66 | - | |
| Franklin H. Moss | M | 75 |
Infinity Discovery, Inc.
| 10 Jahre |
| Christopher M. Lindblom | M | 52 | 8 Jahre | |
| Eric S. Lander | M | 67 |
Infinity Discovery, Inc.
| 15 Jahre |
| Joshua D. Hamermesh | M | 51 | 3 Jahre | |
| Patrick Lee | M | 67 |
Infinity Discovery, Inc.
| 11 Jahre |
| Steven Kafka | M | 54 | 6 Jahre | |
| Yael Margolin | M | 70 | 14 Jahre | |
| Mark A. Clements | M | - |
Massachusetts Institute of Technology
| 3 Jahre |
| Vito Palombella | M | 61 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 14 Jahre |
| Thomas Lynch | M | 63 | 5 Jahre | |
| Allan Reine | M | 49 | 2 Jahre | |
| Steven Holtzman | M | 70 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 18 Jahre |
| Yoo-Hwan Jang | M | 69 |
Massachusetts Institute of Technology
| 3 Jahre |
| Heather DiVecchia | F | - | 6 Jahre | |
| Lance Thibault | M | 58 | 1 Jahre | |
| James Tananbaum | M | 60 |
Infinity Discovery, Inc.
| 11 Jahre |
| Shawn Tomasello | F | 65 | 5 Jahre | |
| Samuel Minzberg | M | 67 |
McGill University
| 11 Jahre |
| Abbey Jenkins | F | - | 2 Jahre | |
| Assaf Segal | M | 51 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 1 Jahre |
| Glenn Ives | M | 62 |
Princess Margaret Cancer Foundation
| 9 Jahre |
| Jolie Siegel | F | 48 | 2 Jahre | |
| Beth A. Marcus | M | - |
Massachusetts Institute of Technology
| 5 Jahre |
| Ruben Ojeda | M | - |
Massachusetts Institute of Technology
| 6 Jahre |
| Peter Zieve | M | 70 |
Massachusetts Institute of Technology
| 3 Jahre |
| Tom A. Stefanick | M | - |
Massachusetts Institute of Technology
| 5 Jahre |
| Jocelyn E. Scott | F | - |
Massachusetts Institute of Technology
| 4 Jahre |
| Meryl Zausner | F | 67 | 3 Jahre | |
| On-kwok Li | M | 69 |
Massachusetts Institute of Technology
| 3 Jahre |
| Terence S. Orstlan | M | - |
McGill University
| 6 Jahre |
| Steven C. Webster | M | 67 |
Massachusetts Institute of Technology
| 5 Jahre |
| J. Wargo | M | 69 |
Massachusetts Institute of Technology
| 6 Jahre |
| Jon Hirschtick | M | - |
Massachusetts Institute of Technology
| 5 Jahre |
| José Baselga | M | 65 | 3 Jahre | |
| Ian Smith | M | 58 | 11 Jahre | |
| Paul Arnison | M | - |
McGill University
| 6 Jahre |
| Caroline Dorsa | F | 64 | 22 Jahre | |
| Richard Bagley | M | 80 |
ProScript, Inc.
 ProScript, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., ProScript, Inc. is a company that develops anti-cancer treatments. The company is based in Cambridge, MA. The company was founded by Tom Maniatis. ProScript was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on July 20, 1999 for $3.35 million. | 4 Jahre |
| John Hector McArthur | M | 90 | 8 Jahre | |
| John J Horan | M | - | 6 Jahre | |
| Kenneth Moch | M | 69 | 8 Jahre | |
| Brian Jacobs | M | 63 |
Massachusetts Institute of Technology
| 5 Jahre |
| Tom Maniatis | M | 80 |
ProScript, Inc.
ProScript, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., ProScript, Inc. is a company that develops anti-cancer treatments. The company is based in Cambridge, MA. The company was founded by Tom Maniatis. ProScript was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on July 20, 1999 for $3.35 million. | - |
| John Robert Chisholm | M | - |
Massachusetts Institute of Technology
| 7 Jahre |
| Chau Khuong | M | 48 | 3 Jahre | |
| Kenneth Bartizal | M | 72 | 20 Jahre | |
| Marino Carol | F | - | 8 Jahre | |
| Paul Alofs | M | - |
Princess Margaret Cancer Foundation
| 15 Jahre |
| Perry Ha | M | 62 |
Massachusetts Institute of Technology
| 6 Jahre |
| Bert Richards | M | - |
Massachusetts Institute of Technology
| 5 Jahre |
| Brian E. Foody | M | - |
Massachusetts Institute of Technology
| 5 Jahre |
| Daphne Karydas | F | 49 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | - |
| Scott Kapnick | M | - | 8 Jahre | |
| Don Shulsinger | M | - |
Massachusetts Institute of Technology
| 6 Jahre |
| Huw Nash | M | 57 | 12 Jahre | |
| Montgomery Alger | M | 67 |
Massachusetts Institute of Technology
| 5 Jahre |
| Zaurie Zimmerman | F | - |
Massachusetts Institute of Technology
| 6 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 84 | 84,00% |
| Kanada | 16 | 16,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Julian Adams
- Persönliches Netzwerk
